CTRI/2020/03/024065Other1 期
A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Suspension (PICS) in Subjects with Locally Recurrent or Metastatic Breast Cancer (MBC).
试验速览
- 阶段
- 1 期
- 状态
- Other
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. The subject has given written, informed consent (or legally acceptable representative /impartial witness when applicable) and is available for the duration of study
- •2. Histologically or cytologically confirmed diagnosis of breast cancer with adequate documentation of prior therapy with an anthracycline unless clinically contraindicated
- •3. Locally recurrent or MBC for which taxane-based therapy is an appropriate treatment option
- •4. Male or female aged greater than equal to 18 years
- •5. ECOG performance status less than equal to 1
- •6. Estimated life expectancy of at least 12 weeks
- •7. Adequate organ and immune system function as indicated by the following laboratory values, obtained less than equal to 2 weeks prior to dosing for Period 1 and Period 2:
- •8. Any chemotherapy, targeted therapy, major surgery, or irradiation must have been completed at least 4 weeks before enrollment (6 weeks for mitomycin C or nitrosurea); immune therapy or hormonal therapy (except palliative bisphosphonate therapy for bone pain) must be completed 2 weeks before enrollment and subjects must have recovered from all toxicities incurred as a result of previous therapy except alopecia; use of targeted therapy or antibody therapy should have been completed for at least 5 half-lives of the respective therapy before enrollment. Use of narcotic analgesics such as dihydrocodeine and medicinal herbs such as St. Johnâ??s Wort, which may act as inhibitors/inducers of CYP2C8 and CYP3A4, must have been discontinued at least 2 weeks and 4 weeks respectively before enrollment
- •9. Subjects of child bearing potential must practice an acceptable method of birth control as judged by the investigator
- •Medically acceptable methods of birth control include the use of either a contraceptive implant or a contraceptive injection (e.g., Depo-Provera•) or an intrauterine device, same sex partner or vasectomized partner or an oral contraceptive taken continually within the past three months and which the subject agrees to continue using during the study
- •To adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following: diaphragm, cervical cap, condom, or a spermicide at least 2 months prior to study entry and must continue to use contraception for the duration of the study
- •10. Female subjects who are postmenopausal for at least 1 year as per investigatorâ??s discretion, or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
- •11. Male subjects enrolled in the trial cannot father a child and are advised to prevent passage of semen to their sexual partner during intercourse using acceptable methods as judged by the investigator for the duration of the study
- •12. Females subjects of child-bearing potential must have a negative urine pregnancy test
- •13. Female subjects must be non-lactating and non-breastfeeding
- •14. Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
排除标准
- •1. Known hypersensitivity to the study drug or their excipients (cholesteryl sulfate, caprylic acid, polyvinylpyrrolidone, ethanol, polyethylene glycol)
- •2. Inability to undergo venipuncture and/or tolerate venous access
- •3. Presence of clinically symptomatic active CNS metastases, including leptomeningial involvement, requiring steroid or radiation therapy
- •4. Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher according to CTCAE, Version 5.0)
- •5. Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study or confound the study
- •6. Presence of pleural/ascitic fluid which cannot be definitively treated prior to dosing and during the PK blood draws in each period (Period 1 and Period 2) and if there is re-accumulation of fluid (greater than 5%) greater than 2 weeks after definitive management
- •7. Positive laboratory exclusion test (HIV, HBsAg, or HCV)
- •8. Treatment with investigational agents or participation in a clinical trial within 30 days of study entry
- •9. Failure of prior taxane therapy for metastatic disease or for adjuvant therapy within previous 6 months of screening visit
- •10. Subjects taking concurrent medications that may act as inhibitors/inducers of CYP2C8 and CYP3A4 within 2 weeks of screening and during Periods 1 and 2
- •11. Evidence or history of bleeding diathesis or coagulopathy within 6 months prior to screening visit
- •12. Uncontrolled cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA), history of hypertensive crisis
- •13. Active clinical infection which in the treating investigatorâ??s opinion renders the subject ineligible or can confound the study
- •14. Serious non-healing wound, ulcer or bone fracture
- •15. Unresolved toxicity higher than CTCAE Version 5.0 Grade 1 (excluding alopecia, anemia) attributed to any prior therapy/procedure
- •16. History of gastrointestinal perforation within 6 months prior to screening visit.
研究者
相似试验
已完成
不适用
Pharmacokinetic study of SPARC1613 and Reference1613CTRI/2016/12/007565Sun Pharma Advanced Research Company Limited142
Unknown
1 期
A Randomized, Open Label,Two Period, Single Dose Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Patients with Breast CancerCTRI/2014/04/004528Sun Pharma Advanced Research Company Ltd72
已完成
不适用
Clinical research study of SPARC1612 in breast cancerCTRI/2016/06/007043Sun Pharma Advanced Research Company Ltd28
已完成
不适用
Randomized, Open Label, Single-Dose, Two Period, Two Treatment, Two Sequence, Cross-over, Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety of Rabeprazole Sodium Delayed-release Capsule 20 mg in Healthy Volunteers.CTRI/2017/07/008985Cadila Healthcare Limited12
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-period, Two-sequence Crossover Bioequivalence Study of Generic Linagliptin/Metformin Hydrochloride Tablets 2.5 mg/1000 mg and Reference Product (TRAJENTA DUO) in Healthy Thai Volunteers under Fed ConditionsBioequivalence Study Healthy Thai VolunteersTCTR20231012008International Bio Service Co., Ltd.40